Pharming Group NV
AEX:PHARM
Pharming Group NV
Research & Development
Pharming Group NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharming Group NV
AEX:PHARM
|
Research & Development
-$88.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-21%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Research & Development
-€45.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-8%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Research & Development
-$139.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-11%
|
|
|
argenx SE
XBRU:ARGX
|
Research & Development
-$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Research & Development
-$328.5m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-35%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Research & Development
-$28.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
Glance View
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
See Also
What is Pharming Group NV's Research & Development?
Research & Development
-88.4m
USD
Based on the financial report for Sep 30, 2025, Pharming Group NV's Research & Development amounts to -88.4m USD.
What is Pharming Group NV's Research & Development growth rate?
Research & Development CAGR 10Y
-21%
Over the last year, the Research & Development growth was -22%. The average annual Research & Development growth rates for Pharming Group NV have been 8% over the past three years , -25% over the past five years , and -21% over the past ten years .
